UK reserves up to 190 million doses of potential Coronavirus vaccines


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ uk-reserves-up-190-million-doses-potential-coronavirus-vaccines
It had already been disclosed in July that the British government had reserved 60 million doses of Valneva's inactivated SARS-CoV-2 vaccine under development.

Britain has secured access to up to 190 million doses of a potential coronavirus vaccine from Valneva in a deal worth as much as 1.37 billion euros, the French-Austrian vaccine firm said Monday.

It had already been disclosed in July that the British government had reserved 60 million doses of Valneva's inactivated SARS-CoV-2 vaccine under development.

The firm said it expects to begin trials of the two-dose vaccine in December and if it is successful for it to become available in the second half of 2021.

The 60 million doses supplied to Britain in 2021 would come for 470 million euros ($557 million).

Britain will then have options on 40 million doses in 2022 and between 30 and 90 million from 2023 to 2025, which would cost 900 million euros.

"We are honored to have been chosen by the UK Government and are eager to partner with them to address this terrible ongoing pandemic," Valneva CEO Thomas Lingelbach was quoted as saying in a statement.

Valneva said the British government has also committed to investing in expanding the company's manufacturing site in Scotland which would allow it to become a major vaccine facility.

"This new agreement could help us vaccinate millions of people across the country, as well as help create a UK vaccine manufacturing facility to speed up access to a potential Covid-19 candidate and boost the country's resilience against future pandemics," said Britain's Business Secretary Alok Sharma.

Britain has struck agreements with several pharmaceutical firms developing vaccines against the novel coronavirus to ensure it has access to an effective inoculation, including BioNTech, Pfizer, Janssen Pharmaceuticals, and Novavax.

Shares in Valneva jumped more than 20 percent in early morning trading in Paris.

Tags : #UK #COVID-19 #Vaccines #190M #British

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026